Updated:
TF Capital
TF Capital is a venture capital fund that invests in early-stage and growing companies in pharmaceutical R&D and biomedical technology. The firm has made 103...
TF Capital
TF Capital is a venture capital fund that invests in early-stage and growing companies in pharmaceutical R&D and biomedical technology. The firm has made 103 investments, including a Series A investment in Vivatides on April 10, 2026. TF Capital has facilitated 15 portfolio exits, with GenFleet Therapeutics exiting on September 19, 2025.
General information
Firm type
Private Equity
Year founded
2013
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
What is TF Capital's investment scope within China?
TF Capital pursues a multi-stage venture and growth-equity strategy spanning seed, early-stage, and pre-IPO investments. The firm's Shanghai headquarters places it at the center of China's largest startup ecosystem. Its approach covers the full private-company lifecycle, giving it flexibility to support portfolio companies across multiple funding rounds.
How does TF Capital's multi-stage structure affect its portfolio construction?
By covering seed through pre-IPO, TF Capital can retain allocation capacity for follow-on rounds without depending entirely on external co-investors. This model also allows the firm to enter positions at the growth stage when earlier-stage funds face limits. In China's regulatory environment, maintaining board continuity across stages is a practical governance mechanism.
What investment stages does TF Capital target?
TF Capital targets early-stage seed and start-up rounds, expansion and late-stage venture, and pre-IPO opportunities. This span positions the firm to deploy capital at company formation and sustain exposure through public-market listing events.
Does TF Capital operate as a renminbi or US-dollar fund?
The firm's fund currency structure is not publicly disclosed. Many Shanghai-based private equity managers operate both renminbi and US-dollar vehicles to serve different limited partner bases and to navigate China's capital controls and Qualified Foreign Limited Partner regimes.
How is TF Capital positioned relative to other Shanghai-based venture firms?
TF Capital's full-lifecycle mandate distinguishes it from pure seed-stage accelerators and from later-stage growth funds that only enter mature companies. This intermediate positioning can appeal to founders seeking a single long-term institutional partner rather than onboarding new investors at each round.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: